EUVIMEDEUVIMED entdecken
Open Access

The HSP90 inhibitor HVH-2930 exhibits potent efficacy against trastuzumab-resistant HER2-positive breast cancer

Minsu Park, Eunsun Jung, Jung Min Park, Soeun Park, Dongmi Ko, Juyeon Seo, Seongjae Kim, Kee Dal Nam, Yong Koo Kang, Lee Farrand, Van-Hai Hoang, Cong-Truong Nguyen und 8 weitere

Theranostics · 2024

DOI: 10.7150/thno.93236 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Theranostics, 2024. Verfasst von Minsu Park und 19 weiteren Autor:innen. Beteiligte Einrichtung: Division of Medical Oncology, Department of Internal Medicine, Korea University College of Medicine, Korea University, Seoul 02841, Republic of Korea. Hauptthemen laut MEDLINE: HSP90 Heat-Shock Proteins, Drug Resistance, Neoplasm, Breast Neoplasms, Trastuzumab. Die Arbeit wurde bisher 14-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HSP90 Heat-Shock ProteinsDrug Resistance, NeoplasmBreast NeoplasmsTrastuzumabErb-b2 Receptor Tyrosine KinasesXenograft Model Antitumor AssaysHumansAnimalsFemaleCell Line, TumorMiceNeoplastic Stem CellsMice, NudeApoptosisCell SurvivalAntineoplastic Agents

Stichwörter der Autor:innen

C-terminal HSP90 inhibitorHER2-positive breast cancerHVH-2930cancer stem cellstrastuzumab resistance

Substanzen

HSP90 Heat-Shock ProteinsTrastuzumabErb-b2 Receptor Tyrosine KinasesAntineoplastic AgentsERBB2 protein, human

Autor:innen und Institutionen

  • Division of Medical Oncology, Department of Internal Medicine, Korea University College of Medicine, Korea University, Seoul 02841, Republic of Korea.
  • Brain Korea 21 Program for Biomedical Science, Korea University College of Medicine, Korea University, Seoul 02841, Republic of Korea.
  • Department of Biomedical Research Center, Korea University Guro Hospital, Korea University, Seoul 08308, Republic of Korea.
  • Adelaide Medical School, Faculty of Health and Medical Sciences, The University of Adelaide, South Australia 5000, Australia.
  • Faculty of Pharmacy, PHENIKAA University, Hanoi 12116, Vietnam.
  • Department of Organic Chemistry, Hanoi University of Pharmacy, Hanoi 10000, Vietnam.

Zitieren

APA

Park, M., Jung, E., Park, J. M., Park, S., Ko, D., Seo, J., Kim, S., Nam, K. D., Kang, Y. K., Farrand, L., Hoang, V. H., Nguyen, C. T., La, M. T., Nam, G., Park, H. J., Ann, J., Lee, J., Kim, Y. J., Kim, J. Y., & Seo, J. H. (2024). The HSP90 inhibitor HVH-2930 exhibits potent efficacy against trastuzumab-resistant HER2-positive breast cancer. Theranostics. https://doi.org/10.7150/thno.93236

Vancouver

Park M, Jung E, Park JM, Park S, Ko D, Seo J, et al. The HSP90 inhibitor HVH-2930 exhibits potent efficacy against trastuzumab-resistant HER2-positive breast cancer. Theranostics. 2024. doi:10.7150/thno.93236

BibTeX
@article{Park2024,
  author = {Park, Minsu and Jung, Eunsun and Park, Jung Min and Park, Soeun and Ko, Dongmi and Seo, Juyeon and Kim, Seongjae and Nam, Kee Dal and Kang, Yong Koo and Farrand, Lee and Hoang, Van-Hai and Nguyen, Cong-Truong and La, Minh Thanh and Nam, Gibeom and Park, Hyun-Ju and Ann, Jihyae and Lee, Jeewoo and Kim, Yoon-Jae and Kim, Ji Young and Seo, Jae Hong},
  title = {The HSP90 inhibitor HVH-2930 exhibits potent efficacy against trastuzumab-resistant HER2-positive breast cancer},
  journal = {Theranostics},
  year = {2024},
  doi = {10.7150/thno.93236}
}
Kostenlos starten →